Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

1.

Prodromal symptoms and remission following first episode psychosis.

Renwick L, Lyne J, Donoghue BO, Owens L, Doyle R, Hill M, McCarthy E, Pilling M, O'Callaghan E, Clarke M.

Schizophr Res. 2015 Jul 14. pii: S0920-9964(15)00340-0. doi: 10.1016/j.schres.2015.07.001. [Epub ahead of print]

PMID:
26187148
2.

Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia.

Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, Silverstein NJ, Smoller JW, Hill M, Goff DC.

JAMA Psychiatry. 2013 May;70(5):481-9. doi: 10.1001/jamapsychiatry.2013.900.

3.

Clozapine: key discussion points for prescribers.

Hill M, Freudenreich O.

Clin Schizophr Relat Psychoses. 2013 Jan;6(4):177-85. doi: 10.3371/CSRP.HIFR.01062013. Review.

PMID:
23302447
4.

Prospective relationship of duration of untreated psychosis to psychopathology and functional outcome over 12 years.

Hill M, Crumlish N, Clarke M, Whitty P, Owens E, Renwick L, Browne S, Macklin EA, Kinsella A, Larkin C, Waddington JL, O'Callaghan E.

Schizophr Res. 2012 Nov;141(2-3):215-21. doi: 10.1016/j.schres.2012.08.013. Epub 2012 Sep 21.

PMID:
23006501
5.

Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population.

Viron M, Baggett T, Hill M, Freudenreich O.

Am J Med. 2012 Mar;125(3):223-30. doi: 10.1016/j.amjmed.2011.05.002. Review.

PMID:
22340915
6.

Perceptions of involuntary admission and risk of subsequent readmission at one-year follow-up: the influence of insight and recovery style.

O'Donoghue B, Lyne J, Hill M, O'Rourke L, Daly S, Larkin C, Feeney L, O'Callaghan E.

J Ment Health. 2011 Jun;20(3):249-59. doi: 10.3109/09638237.2011.562263.

PMID:
21574790
7.

Treatment adherence in schizophrenia and schizoaffective disorder.

Goff DC, Hill M, Freudenreich O.

J Clin Psychiatry. 2011 Apr;72(4):e13. doi: 10.4088/JCP.9096tx6cc.

PMID:
21527119
8.

Folate supplementation in schizophrenia: a possible role for MTHFR genotype.

Hill M, Shannahan K, Jasinski S, Macklin EA, Raeke L, Roffman JL, Goff DC.

Schizophr Res. 2011 Apr;127(1-3):41-5. doi: 10.1016/j.schres.2010.12.006. Epub 2011 Feb 21.

PMID:
21334854
9.

Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder.

Goff DC, Hill M, Freudenreich O.

J Clin Psychiatry. 2010;71 Suppl 2:20-6. doi: 10.4088/JCP.9096su1cc.04. Review.

PMID:
21190649
10.

The treatment of cognitive impairment in schizophrenia.

Goff DC, Hill M, Barch D.

Pharmacol Biochem Behav. 2011 Aug;99(2):245-53. doi: 10.1016/j.pbb.2010.11.009. Epub 2010 Nov 27. Review.

11.

Nonadherence to medication four years after a first episode of psychosis and associated risk factors.

Hill M, Crumlish N, Whitty P, Clarke M, Browne S, Kamali M, Kinsella A, Waddington JL, Larkin C, O'Callaghan E.

Psychiatr Serv. 2010 Feb;61(2):189-92. doi: 10.1176/appi.ps.61.2.189.

PMID:
20123826
12.

Involuntary admission from the patients' perspective.

O'Donoghue B, Lyne J, Hill M, Larkin C, Feeney L, O'Callaghan E.

Soc Psychiatry Psychiatr Epidemiol. 2010 Jun;45(6):631-8. doi: 10.1007/s00127-009-0104-7. Epub 2009 Aug 11.

PMID:
19669680
13.

Systemic contact dermatitis of the eyelids caused by formaldehyde derived from aspartame?

Hill AM, Belsito DV.

Contact Dermatitis. 2003 Nov;49(5):258-9. No abstract available.

PMID:
14996049
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk